Lumos Diagnostics Holdings Ltd. (AU:LDX) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Lumos Diagnostics has secured a national contract with MediGroup for its rapid point-of-care test, FebriDx, which has been FDA-cleared for helping diagnose acute respiratory infections. The partnership with MediGroup, the largest non-acute care group purchasing organization in the US, will significantly expand FebriDx’s distribution to over 30,000 members, including a range of healthcare facilities. This marks a major milestone for Lumos in strengthening its market presence in the United States.
For further insights into AU:LDX stock, check out TipRanks’ Stock Analysis page.